logo-loader

Prescient Therapeutics begins dose escalation for ovarian cancer

Published: 14:30 08 Dec 2016 AEDT

rsz_shutterstock_314242085
Prescient Therapeutics begins dose escalation for ovarian cancer

PTX-200 inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia.

The trial is being conducted at the H. Lee Moffitt Cancer Center in Florida, U.S.

The Phase 1b/2 trial combines PTX-200 with cisplatin (standard of care chemotherapy) in patients with recurrent or persistent platinum-resistant ovarian cancer.

Hyper-phosphorylated Akt is a key feature of platinum-resistant ovarian cancer, and these patients no longer respond to conventional chemotherapy.

This is a major problem in the treatment of ovarian cancer globally and results in extremely low survival rates.

There are currently very limited treatment options for women with platinum-resistant ovarian cancer.

Early studies have shown that PTX-200 sensitises chemo-resistant ovarian cancer cells to the chemotherapy drug cisplatin.

Furthermore, PTX-200 was successful in synergising with cisplatin to enhance cell death in ovarian cancer cells.

Ovarian cancer is the fifth most common cancer in women in the U.S. and the fourth most common cause of cancer deaths.

PTX-200 is a promising drug candidate, which has great potential as a new treatment for this problematic disease.

Prescient is well funded to progress trials of the drug with a cash balance of $9.38 million as at 30 September 2016.

Prescient Therapeutics showcases cell therapy data at prestigious ISCT...

Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting. The team briefed an expert cell therapy audience on...

on 16/6/23